Serum distribution of two contraceptive progestins: 3-ketodesogestrel and gestodene.
A cross-over study of two oral contraceptive formulations, containing 30 micrograms ethinylestradiol in combination with 150 micrograms desogestrel (Marvelon) or 75 micrograms gestodene (Femovan), has been performed to compare the serum distribution and pharmacokinetics of gestodene and the active metabolite of desogestrel, namely 3-ketodesogestrel. Serum concentrations of both sex hormone-binding globulin (SHBG) and corticosteroid-binding globulin (CBG) were also measured and were increased more than 3-fold and 2-fold, respectively, on day 21 of the treatment cycle, with no statistically significant difference between treatment groups. In addition, 35 days after ingestion of either oral contraceptive had ceased, the serum SHBG and CBG concentrations were similar to the pretreatment values. During treatment cycles, increased serum SHBG levels were associated with a redistribution of 3-ketodesogestrel and gestodene such that the non-protein-bound (NPB) and albumin-bound fractions were reduced in concert with an increase in the relative proportions bound to SHBG. The proportion of gestodene bound to SHBG was consistently higher than that observed for 3-ketodesogestrel, and this undoubtedly reflects the higher affinity of SHBG for gestodene (Kd = 1.2 nM at 37 degrees C) when compared to 3-ketodesogestrel (Kd = 4.7 nM at 37 degrees C). It also probably accounts, in part, for the much higher total serum levels of gestodene (8.58 nmol/L) when compared to 3-ketodesogestrel (2.37 nmol/L) during the treatment cycles. Consequently, the absolute amounts of NPB, non-SHBG-bound, and SHBG-bound gestodene are significantly higher than those measured for 3-ketodesogestrel. It is concluded that ethinylestradiol-induced increases in serum SHBG levels during treatment with Marvelon or Femovan, influenced the distribution and total amount of 3-ketodesogestrel and gestodene in serum, respectively, and that this, combined with the higher affinity of SHBG for gestodene, results in a greater amount of bioavailable gestodene compared to 3-ketodesogestrel, despite the smaller dose of gestodene administered.
Hammond
G L
GL
Department of Obstetrics and Gynecology, University of Western Ontario, London, Canada.
Bocchinfuso
W P
WP
Orava
M
M
Smith
C L
CL
van den Ende
A
A
van Enk
A
A
D000328:Adult; D001682:Biological Availability; D003277:Contraceptives, Oral, Combined / Q000493:pharmacokinetics*; D018592:Cross-Over Studies; D017135:Desogestrel / Q000097:blood* / Q000493:pharmacokinetics; D004997:Ethinyl Estradiol / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D007700:Kinetics; D009652:Norpregnenes / Q000097:blood* / Q000493:pharmacokinetics; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism; D014156:Transcortin / Q000378:metabolism
D003277:Contraceptives, Oral, Combined; D009652:Norpregnenes; D012738:Sex Hormone-Binding Globulin; C033273:Gestodene; C044815:etonogestrel; D004997:Ethinyl Estradiol; D017135:Desogestrel; D014156:Transcortin